8-K filing — SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Filed: 2026-10-29 AccNo: 0001356576-26-000050 Size: 461 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Indivior Reports Q3 2026 Results and Confirms Imminent Merger with Supernus
Indivior Pharmaceuticals reported its third-quarter 2026 financial results and confirmed that its merger with Supernus Pharmaceuticals is expected to close on November 2, 2026.
Newron Pharmaceuticals Completes Enrollment in Phase 3 ENIGMA-TRS 1 Study for Evenamide
Newron Pharmaceuticals has finished patient enrollment for its Phase 3 study of evenamide, a glutamate modulator for which Supernus Pharmaceuticals holds U.S. marketing rights.